
FDA Grants Priority Review to Sonesitatug Vedotin in Pretreated CLDN18.2+ Gastric/GEJ Cancers
The FDA granted priority review to sonesitatug vedotin in second- and later-line CLDN18.2-positive gastric, GEJ, or esophageal adenocarcinoma, with a decision expected in the second quarter of 2027.
The FDA has accepted a biologics license application for sonesitatug vedotin and granted it priority review for the second- and later-line treatment of patients with locally advanced or metastatic gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinoma with Claudin 18.2 (CLDN18.2) expression on at least 25% of tumor cells at any staining intensity, according to a news release from the developer, AstraZeneca.1 The Prescription Drug User Fee Act date is anticipated in the second quarter of 2027.
What data supported the priority review?
The application is based on results from the phase 3 CLARITY-Gastric01 trial (NCT06346392), which were
Progression-free survival (PFS) by blinded independent central review, the other dual primary end point, was 4.2 vs 3.8 months in the intention-to-treat population (HR, 0.77; 95% CI, 0.62-0.96; P = .053193), which did not reach statistical significance.
In exploratory subgroup analyses not adjusted for multiplicity, the OS HR was 0.88 (95% CI, 0.60-1.30) in second-line patients and 1.08 (95% CI, 0.68-1.71) in patients with GEJ cancer or esophageal adenocarcinoma.
No new safety signals and fewer grade 3 or higher treatment-related adverse effects were observed with sonesitatug vedotin.1 Nausea (54.4% vs 26.6%), decreased appetite (43.3% vs 24.2%), and vomiting (41.0% vs 24.6%) were more common with sonesitatug vedotin, while grade 3 or higher neutropenia was less common (10.3% vs 25.4%).
What was the design of CLARITY-Gastric01?
CLARITY-Gastric01 is a randomized, open-label, sponsor-blinded, multicenter trial conducted at 175 centers in 19 countries. In the dose-selection stage, patients were randomly assigned 1:1:1 to sonesitatug vedotin at 2.2 mg/kg, sonesitatug vedotin at 1.8 mg/kg, or investigator's choice of therapy, each given every 3 weeks. The second stage continued with 2.2 mg/kg as the recommended phase 3 dose. The trial enrolled 594 patients with previously treated, CLDN18.2-positive advanced or metastatic disease; 267 were randomly assigned to sonesitatug vedotin at 2.2 mg/kg and 265 to investigator's choice.
Investigator's choice in the second-line setting was ramucirumab (Cyramza) plus paclitaxel, paclitaxel, or docetaxel. In the third-line-or-later setting, options were irinotecan, trifluridine/tipiracil (Lonsurf), or apatinib (China only). The dual primary end points were PFS by blinded independent central review in the second-line-or-later setting and OS in the third-line-or-later setting; OS in the second-line-or-later setting was a key secondary end point.
What is sonesitatug vedotin and where else is it under review?
Sonesitatug vedotin is an antibody-drug conjugate (ADC) made up of an anti-CLDN18.2 antibody, a protease-degradable linker, and a monomethyl auristatin E payload. Sonesitatug vedotin has an orphan drug designation from the FDA and the European Commission for gastric and GEJ cancers and a breakthrough designation in China for second-line gastric cancer. Applications are under review in the European Union, China, and several other countries.
“After progressing on first-line treatment, patients with Claudin 18.2-positive advanced gastric cancer have no targeted options. [Sonesitatug vedotin] is the first ADC targeting Claudin 18.2 to improve [OS] for patients compared with current standard of care in this setting and across a population that encompasses a much broader definition of Claudin 18.2 positivity than for current drugs,” said Susan Galbraith, executive vice president of Oncology Haematology R&D at AstraZeneca, in the press release.1 “This priority review of our submission speaks to the significant potential of this medicine and accelerates the ability to bring forward a new targeted approach and alternative to traditional chemotherapy for thousands of patients in the US.”
References
- Sonesitatug vedotin granted Priority Review in the US for 2nd and later-line treatment of patients with CLDN18.2-positive advanced gastric/GEJ cancers. News release. AstraZeneca. November 19, 2026. Accessed November 19, 2026. https://tinyurl.com/4m8rnj6b
- Xu RH, Janjigian Y, Chen MH, et al. CLARITY-Gastric01: a phase 3 study of sonesitatug vedotin (Sone-Ve, AZD0901) in second or later-line advanced or metastatic Claudin 18.2-positive gastroesophageal carcinoma. Presented at: 2026 European Society for Medical Oncology Congress; October 23-27, 2026; Madrid, Spain. Abstract LBA7.
Related to this article








